Abstract
Pregnancy in rheumatic disease patients is increasingly common: more effective therapies, recognition of pregnancy risk factors, and improved obstetric care provide many patients the option of pursuing pregnancy. Optimizing maternal and fetal outcomes relies on identifying patients without serious end-organ damage for whom pregnancy is feasible, planning for pregnancy during a period of well-controlled disease, and ensuring that medications are both effective and compatible with pregnancy. For any rheumatic disease patient, pre-pregnancy assessment of risk for maternal and obstetric complications is critical, as is effective counseling of both the patient and her partner regarding risk and prognosis. Rheumatic disease patients benefit from coordinated rheumatology and obstetric care that is individualized to the patient’s diagnosis and particular clinical situation: pregnancy outcome is optimized when the rheumatologist, obstetrician, other involved specialists and patient establish a plan of care early and communicate frequently.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Owen J, Hauth JC. Polyarteritis nodosa in pregnancy: a case report and brief literature review. Am J Obstet Gynecol. 1989;160(3):606–9.
Bédard E, Dimopoulos K, Gatzoulis MA. Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur Heart J. 2009;30(3): 256–65.
Imbasciati E, Gregorini G, Cabiddu G, Gammaro L, Ambroso G, Del Giudice A, et al. Pregnancy in CKD stages 3 to 5: fetal and maternal outcomes. Am J Kidney Dis. 2007;49: 753–62.
Bramham K, Soh MC, Nelson-Piercy C. Pregnancy and renal outcomes in lupus nephritis: an update and guide to management. Lupus. 2012;21:1271–83.
Smythe A, Oviveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD. A systematic review and metalaysis of pregnancy outcomes in patients with systemic lupus erythematosusu and lupus nephritis. Clin J Am Soc Nephrol. 2010;5:2060–8.
Chakravarty EF, Colon I, Langer ES, Nix DA, El-Sayed YY, Genovese MC, et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by SLE. Am J Obstet Gynecol. 2005;192:1897–904.
Andrade R, Sanchez ML, Alarcon GS, Fessler BJ, Fernandez M, Bertoli AM, et al. Adverse pregnancy outcomes in women with systemic lupus erythematosus from a multiethnic US cohort: LUMINA (LVI). Clin Exp Rheumatol. 2008;26:268–74.
Clowse MEB, Magder LS, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum. 2005;52:514–21.
Le Thi HD, Wechlser B, Vauthier-Brouzes D, Seebacher J, Lefebvre G, Bletry O, et al. Outcome of planned pregnancy in systemic lupus erythematosus: a prospective study on 62 pregnancies. Br J Rheumatol. 1997;36:772–7.
Doria A, Bajocchi G, Ronon M, Salvarani C. Pre-pregnancy counseling of patients with vasculitis. Rheumatology (Oxford). 2008;47:iii3–5.
Steen V, Chakravarty EF. Pregnancy. In: Scleroderma. Springer, New York, NY, USA; 2012. p. 547–57.
Wallenius M, Skomsvoll JF, Irgens LM, Salvesen KÅ, Nordvåg BY, Koldingsnes W, et al. Pregnancy and delivery in women with chronic inflammatory arthritides with a specific focus on first birth. Arthritis Rheum. 2011;63(6):1534–42.
de Man YA, Hazes JM, van der Heide H, Willemsen SP, de Groot CJ, Steegers EA, et al. Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study. Arthritis Rheum. 2009;60(11):3196–206.
Kainz A, Harabacz I, Cowlrick IS, Gadgil S, Hagiwara D. Analysis of 100 pregnancy outcomes in women treated systemically with tacrolimus. Transpl Int. 2000;13(S1):S299–300.
Mok CC, Tong KH, To CH, Siu YP, Au TC. Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int. 2005;68(2):813–7.
Alsuwaida A. Successful management of systemic lupus erythematosus nephritis flare-up during pregnancy with tacrolimus. Mod Rheumatol. 2011;21(1):73–5.
Levy RA, Vilela VS, Cataldo MJ, Ramos RC, Duarte JLMB, Tura BR, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus. 2001;10(6): 401–4.
Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006;54(11):3640–7.
Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, Khamashta MA, Kim MY, Saxena A, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation. 2012;126(1): 76–82.
Askie LM, Duley L, Henderson-Smait DJ, Stewart LA, on behalf of the PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007;369:1791–98.
Lockshin MD, Kim M, Laskin CA, Guerra M, Branch D, Merrill J, et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum. 2012;64(7):2311–8.
Boumpas DT, Austin HA, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med. 1993;119(5):366–9.
Somers EC, Marder W, Christman GM, Ognenovski V, McCune WJ. Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum. 2005;52(9):2761–7.
Clowse MEB, Jamison M, Myers E, James AH. A national study of the complications of lupus in pregnancy. Am J Obstet Gynecol. 2008;199:127.e1–6.
Andrade RM, McGwin G, Alarcon GS, Sanchez ML, Bertoli AM, Fernandez M, et al. Predictors of postpartum damage accrual in systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (XXXVIII). Rheumatology. 2006;45:1380–284.
Ruiz-Irastorza G, Lima F, Alves J, Khamashta MA, Simpson J, Hughes GR, et al. Increased rate of lupus flare in pregnancy and the puerperium: a prospective study of 78 pregnancies. Br J Rheumatol. 1996;35:133–8.
Boffa MC, Lachassinne E. Infant perinatal thrombosis and antiphospholipid antibody: a review. Lupus. 2007;16(18):634–41.
Messina S, Fagiolari G, Lamperti C, Cavaletti G, Prelle A, Scarlato G, et al. Women with pregnancy-related polymyositis and high serum CK levels in the newborn. Neurology. 2002;58(3):482–4.
Schlieben DJ, Korbet SM, Kimura RE, Schwartz MM, Lewis EJ. Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs. Am J Kidney Dis. 2005;45(4):758–61.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Sammaritano, L.R., Bermas, B.L. (2014). General Approach: Pre-pregnancy Assessment of the Rheumatic Disease Patient. In: Sammaritano, L., Bermas, B. (eds) Contraception and Pregnancy in Patients with Rheumatic Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0673-4_3
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0673-4_3
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-0672-7
Online ISBN: 978-1-4939-0673-4
eBook Packages: MedicineMedicine (R0)